Abstract
Five years after the US anthrax attacks, and more than two years after BioShield legislation was ratified, a survey reveals that biodefense funding has thus far produced only a handful of products for clinical development.
MeSH terms
-
Biotechnology / economics*
-
Bioterrorism / economics*
-
Bioterrorism / prevention & control
-
Civil Defense / economics*
-
Clinical Medicine / economics*
-
Drug Industry / economics*
-
Technology Transfer*
-
United States
-
Vaccines / economics*